

# Jann Arends

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5164218/publications.pdf>

Version: 2024-02-01

36  
papers

5,830  
citations

393982

19  
h-index

288905

40  
g-index

49  
all docs

49  
docs citations

49  
times ranked

6686  
citing authors

#	ARTICLE	IF	CITATIONS
1	The importance of protein sources to support muscle anabolism in cancer: An expert group opinion. <i>Clinical Nutrition</i> , 2022, 41, 192-201.	2.3	30
2	Energy and protein intake may have an impact on survival in patients with advanced cancer. <i>Clinical Nutrition</i> , 2022, 41, 266-267.	2.3	2
3	Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 521-530.	0.5	12
4	COVID-19 in Patients with Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 315-331.	0.8	3
5	Supportive Care: Low Cost, High Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 240-250.	1.8	6
6	ESPEN practical guideline: Clinical Nutrition in cancer. <i>Clinical Nutrition</i> , 2021, 40, 2898-2913.	2.3	472
7	Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey. <i>Clinical Nutrition ESPEN</i> , 2021, 45, 433-441.	0.5	21
8	ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. <i>Clinical Nutrition</i> , 2021, 40, 5196-5220.	2.3	74
9	Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey. <i>Clinical Nutrition</i> , 2020, 39, 585-591.	2.3	31
10	Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. <i>Supportive Care in Cancer</i> , 2020, 28, 979-1010.	1.0	22
11	Supplemental parenteral nutrition: decisions based on weak evidence. <i>ESMO Open</i> , 2020, 5, e000831.	2.0	1
12	Assessing Evidence and the Need for High-Quality Research in Clinical Nutrition. <i>Nutrition in Clinical Practice</i> , 2019, 34, 477-477.	1.1	0
13	From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988008.	1.4	68
14	How to feed patients with gastrointestinal mucositis. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 168-173.	0.5	9
15	Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey. <i>Clinical Nutrition</i> , 2018, 37, 728-738.	2.3	107
16	Cancer cachexia: Diagnosis, assessment, and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 127, 91-104.	2.0	140
17	Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. <i>Clinical Nutrition</i> , 2018, 37, 1794-1797.	2.3	77
18	ESPEN expert group recommendations for action against cancer-related malnutrition. <i>Clinical Nutrition</i> , 2017, 36, 1187-1196.	2.3	758

#	ARTICLE	IF	CITATIONS
19	ESPEN guidelines on nutrition in cancer patients. <i>Clinical Nutrition</i> , 2017, 36, 11-48.	2.3	1,855
20	Multimodale Therapie bei Tumorkachexie. , 2017, , 80-87.		0
21	ErnÄhrungstherapie bei Tumorkachexie. , 2017, , 88-101.		0
22	ESPEN guidelines on chronic intestinal failure in adults. <i>Clinical Nutrition</i> , 2016, 35, 247-307.	2.3	554
23	ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. <i>Clinical Nutrition</i> , 2015, 34, 171-180.	2.3	473
24	Quality of care for cancer patients on home parenteral nutrition: development of key interventions and outcome indicators using a two-round Delphi approach. <i>Supportive Care in Cancer</i> , 2013, 21, 1373-1381.	1.0	23
25	Understanding the mechanisms and treatment options in cancer cachexia. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 90-99.	12.5	729
26	A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients. <i>Clinical Nutrition</i> , 2013, 32, 466-467.	2.3	11
27	Comment on van den Berg et al. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012, 36, 504-504.	1.3	1
28	Vitamin D in Oncology. <i>Research in Complementary Medicine</i> , 2011, 18, 2-2.	2.2	7
29	Palliative Treatment: Anticancer, Antisymptom, or End-of-Life Care?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4591-4591.	0.8	3
30	Marine phospholipidsâ€™a promising new dietary approach to tumor-associated weight loss. <i>Supportive Care in Cancer</i> , 2010, 18, 159-170.	1.0	55
31	To Live or Not to Live. <i>Journal of Parenteral and Enteral Nutrition</i> , 2010, 34, 450-451.	1.3	5
32	Metabolism in cancer patients. <i>Anticancer Research</i> , 2010, 30, 1863-8.	0.5	20
33	Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients â€™ Results of a Phase II Study. <i>Oncology Research and Treatment</i> , 2007, 30, 629-635.	0.8	33
34	Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. <i>Lipids in Health and Disease</i> , 2007, 6, 17.	1.2	130
35	Reply to Dr. Tisdale's letter. <i>Clinical Nutrition</i> , 2007, 26, 163.	2.3	0
36	ErnÄhrung bei Tumorpatienten: Unzureichend beachtet. , 0, , .		0